Our Heritage

1995
MethylGene, Inc. Established

MethylGene, Inc. is established in Canada and listed on the Canadian Exchange.

2012
Charles Baum, M.D., Ph.D. Appointed President & CEO

Charles Baum is appointed President & CEO. He was previously the SVP of Global Biotherapeutic Clinical Research for Pfizer, Inc.

2013
Mirati Therapeutics, Inc. Founded

Company relocated headquarters to San Diego and Mirati Therapeutics is created (Mirati loosely translated means “targeted” in Italian). Mirati is listed as MRTX on NASDAQ.

2014
Sitravatinib Clinical Program Initiates

Phase 1/1b clinical trials of sitravatinib, a multi-kinase inhibitor asset that originated with MethylGene, begin and continue to advance.

2014
Mirati Enters Into Collaboration With Array to Target KRAS G12C

Thought to be “undruggable”, data is published showing it’s possible to target the G12C protein. In 2014, Mirati & Array set out to create a successful molecule.

2019
First Patient Treated with MRTX849, a KRAS G12C Inhibitor

January 2019, first patient in Phase 1/2 clinical trial of MRTX849, a direct KRAS G12C inhibitor, is dosed and shows first clinical data in October 2019.

2019
Phase 3 Sitravatinib Trial Begins Enrolling

SAPPHIRE trial kicks off mid-2019 and begins enrolling patients.

2020
Showcasing Discovery Research Portfolio in Three Areas

Early in 2020, KRAS G12D inhibitor candidates advance into IND-enabling studies. The portfolio continues to advance and diversify as other preclinical assets in various solid tumors are evaluated.